GSK Adds Positive Phase 3 Lung Cancer Data, Ends Alector Partnership
GSK-backed Ris-Rez posts positive Phase 3 survival data in small-cell lung cancer as the company moves to end its collaboration with Alector.
Read original at benzingaStocks · News reference
8-K filing — Alector, Inc. (ALEC)
Filed: 2026-07-08 AccNo: 0001193125-26-298526 Size: 148 KB Item 1.02: Termination of a Material Definitive Agreement
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- edgar
- Observed
- Jul 8, 2026, 8:05 PM
- Checked
- Jul 8, 2026, 8:05 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading